8/29/2020
BELUMOSUDIL (KD025) For Patients with Chronic Graft Versus Host Disease (cGVHD): Long Term Follow Up of a Phase 2A Study (KD025 208).
European Society for Blood and Bone Marrow Transplantation.
2020.
View 8/29/2020
Analysis of the ROCKstar Study: A Phase 2, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of BELUMOSUDIL (KD025) in Subjects With cGVHD.
European Society for Blood and Bone Marrow Transplantation.
2020.
View 5/27/2020
Presentation and Management of cGVHD in Real-World Clinical Practice: A Medical Chart Audit.
European Hematology Association.
2020.
View 2/23/2020
Interim Analysis of KD025-213: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Chronic Graft Versus Host Disease (cGVHD) after at Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study).
Transplantation and Cellular Therapy Meetings.
2020.
View 2/19/2020
KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) Long-term Follow-up of a Phase 2a Study (KD025-208).
Transplantation and Cellular Therapy Meetings.
2020.
View 12/9/2019
Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation (HCT): A U.S. Claims Analysis.
ASH Annual Meeting and Exposition.
2019.
View
11/11/2020
A novel human anti-PD1/IL15 bi-functional protein with robust anti-tumor activity and low systemic toxicity.
The Society for Immunotherapy of Cancer.
2020.
View 6/24/2020
Anti-PD-L1/IL15 fusion protein KD033 demonstrated efficient T cell redirected killing of PD-L1 expressing target cells and in vivo efficacy that correlated to its retention in tumors.
American Association of Cancer Research.
2020.
View 6/24/2020
A novel anti-PD1-IL-15 immunocytokine potentiates anti-tumor T cell activity of PD-1 checkpoint blockade and IL-2/15R-beta-gamma agonism.
American Association of Cancer Research.
2020.
View 12/12/2019
Anti-PDL1/IL-15 fusion protein increases efficacy-associated rare effector cells in cynomolgus monkey and mouse peripheral blood.
European Society for Medical Oncology.
2020.
View 11/1/2019
Synergistic efficacy of anti-PD-L1/IL-15 fusion protein in combination with anti-CTLA-4 antibody in a murine orthotopic 4T1 breast carcinoma model.
Society for Immunotherapy of Cancer.
2019.
View
1/14/2018
Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10.
The Journal of Immunology.
2018.
Read More 6/19/2016
ROCK2 signaling is required to induce a subset of T follicular helper cells through opposing effects on STATs in autoimmune settings.
Sci. Signal.
2016.
Read More 6/16/2016
Isoform-specific targeting of ROCK proteins in immune cells.
Small GTPases.
2016.
Read More 4/28/2016
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism.
Blood.
2016.
Read More 4/1/2015
ROCKing cytokine secretion balance in human T cells.
Cytokine.
2015.
Read More 11/25/2014
Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.
PNAS.
2014.
Read More 1/1/2014
Selective ROCK2 inhibition in focal cerebral ischemia.
ANA.
2014.
Read More